Aurobindo Q1 profit seen up 30%, US biz may support revenue -:- Equity Research

Aurobindo Pharma 's profit in April-June quarter may jump 29.6 percent year-on-year to Rs 560.3 crore and revenue is seen rising 15 percent to Rs 3,810.7 crore, according to average of estimates of analysts polled by CNBC-TV18. Operating profit is likely to surge 24.1 percent to Rs 899.2 crore and margin may expand 180 basis points to 23.6 percent on yearly basis. Expectations -Revenue growth may be led by sustained traction in the US -US business is around 58 percent of formulation sales -US business is likely to grow around 30 percent YoY on the back of 30 new drug launches over past 1 year -Company got 13 approvals from drugs in Q1FY17 itself -Generic versions of Tricor, Valcyte, Vimpat, Vfend & injectable Eptifitabine may drive US growth -Europe sales bounced back in Q4FY16 to 9 percent growth, however depreciation of pound & euro may weigh in June quarter. -Antiretroviral (ARV) drugs sales have been lumpy. Analysts expect around 5-6 percent growth atleast YoY